Analyst Research

Report Title Price
Provider: GlobalData
$250.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma A/S Updates on Lyxumia Commercial Roll-Out Reported by Sanofi


Thursday, 1 Aug 2013 01:32am EDT 

Zealand Pharma A/S announced that Sanofi has provided an update on the commercial roll-out of Lyxumia, a once-daily prandial GLP-1 receptor agonist invented by Zealand for the treatment of Type 2 diabetes with world-wide rights to develop and market the product licensed to Sanofi. In February 2013, Lyxumia was granted approval in the European Union and since then it has been launched by Sanofi in the first European markets, including Germany, some Scandinavian markets, and the United Kingdom. Lyxumia has also been approved in Mexico and Australia and in June 2013 Lyxumia received approval in JapanFurther commercial roll-out of the product is expected in 2013. In the United States, the product is undergoing regulatory review by the Food and Drug Administration (FDA) following their acceptance in February 2013 of the New Drug Application (NDA) submitted by Sanofi. 

Company Quote

65.5
-0.5 -0.76%
24 Jul 2014